As CTNNB1-mutated cases proved to show an immune-high profile (Nguyen et al. 2022) and these cases are mostly HCC-type cHCC-ICCs, they might be resistant at ICPIs (Akiba et al. 2024). This evidence concerns the gene CTNNB1 and hepatocellular carcinoma.